Drugs / PEP-CMV: Component A
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02864368 | Dec 2016 → Jun 2020 | glioblastoma | Eric Thompson, M.D. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEP-CMV: Component A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02864368 ↗ |
| Modality | Peptide | “500 µg of PEP-CMV Component A (a synthetic long peptide) mixed with Montanide ISA-51 intradermally administered” NCT02864368 ↗ |
| Route | Other | “intradermally administered” NCT02864368 ↗ |